Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 31 clinical trials
Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes

NOAC edoxaban is superior to current therapy to pre-vent stroke, systemic embolism, or cardiovascular death in patients with AHRE and at least two stroke risk factors but without AF. The trial will be

  • 0 views
  • 23 Jan, 2021
  • 16 locations
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)

The purpose of this study is to investigate the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOAC) in atrial fibrillation patients with intermediate stroke risk (CHA2DS2

  • 0 views
  • 25 Jan, 2021
Apixaban for Prevention of Post-angioplasty Thrombosis of Hemodialysis Vascular Access

without the need for titration, which should be more effective in the critical period early after thrombectomy. NOAC have almost replaced the role of VKA for the prevention of stroke in patients with

  • 0 views
  • 25 Jan, 2021
  • 2 locations
Study of Rivaroxaban for CeREbral Venous Thrombosis

SECRET examines the safety of rivaroxaban versus standard-of-care for treatment of symptomatic cerebral venous thrombosis, initiated within 14 days of diagnosis.

  • 1 views
  • 25 Jan, 2021
  • 13 locations
Amplatzer Amulet LAAO vs. NOAC

The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke

embolism
vitamin k
noac
electrocardiogram
left atrial appendage occlusion
  • 7 views
  • 23 Sep, 2021
  • 73 locations
Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI

A real world registry to compare dual therapy with Dabigatran/Ticagrelor to dual therapie with Dabigatran/Clopidogrel in patients with an indication for NOAC undergoing PCI in the setting of ACS

  • 0 views
  • 08 May, 2021
  • 1 location
Non-warfarin Oral AntiCoagulant Resumption After Gastrointestinal Bleeding in Atrial Fibrillation Patients

Current clinical society guidelines and statements are non-specific and relatively open-ended regarding the optimal timing to restart non-warfarin oral anticoagulant (NOAC) after

  • 5 views
  • 25 Jan, 2021
  • 3 locations
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study

vitamin k antagonist
edoxaban
rivaroxaban
vitamin k
noac
  • 35 views
  • 22 Jan, 2021
  • 25 locations
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents

Atrial fibrillation patients with risk factors for stroke and systemic embolism require long-term anticoagulant therapy. Recently, non-vitamin K antagonist oral anticoagulant (NOAC) has shown

vitamin k antagonist
embolism
antiplatelet agents
rivaroxaban
vitamin k
  • 0 views
  • 23 Sep, 2021
  • 1 location
Left Atrial Appendage Occlusion Versus Novel Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation

warfarin for prevention of the combined endpoint of stroke, major bleeding and cardiovascular mortality. However, studies comparing LAAO to therapy with novel oral anticoagulants (NOAC) have not been

edoxaban
left atrial appendage occlusion
warfarin
cerebral infarction
atrial fibrillation
  • 9 views
  • 27 Jan, 2021
  • 12 locations